Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Solid Tumors, Adult 1Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Diarrhea 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasms 1

Interventions

Carboplatin 98Pemetrexed 70pembrolizumab 68Cisplatin 59Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × Drugs, Investigational × Clear all
NCT00034957 2012-02-16

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

Pfizer

Phase 2 Completed
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡